PET imaging has become an integral component of the diagnosis and management of a substantial number of lymphatic and solid malignancies. One of the greatest dilemmas in prostate cancer remains the need for greater personalization of treatment recommendations based on the true extent of disease, so that patients with extraprostatic, micrometastatic disease can be identified early and managed accordingly. These sites currently remain under the level of detection with standard imaging and continue to confound clinicians. Novel PET tracers to complement anatomic data from CT and MR imaging can truly make a difference, and ongoing research holds the greatest promise.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cpet.2009.05.005 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!